Ikena Oncology (IKNA)
(Delayed Data from NSDQ)
$1.72 USD
+0.03 (1.78%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $1.72 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IKNA 1.72 +0.03(1.78%)
Will IKNA be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for IKNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IKNA
Best Momentum Stocks to Buy for July 12th
New Strong Buy Stocks for July 12th
IKNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -29.05% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround
Down -33.01% in 4 Weeks, Here's Why Ikena Oncology, Inc. (IKNA) Looks Ripe for a Turnaround
Other News for IKNA
Ikena Oncology’s Gamble: Slashing Workforce by Half Could Derail Strategic Plans
Ikena Oncology’s IK-595 Shows Promising Potential as a Best-in-Class Dual RAF/MEK Inhibitor: Analyst Maintains Buy Rating
Wedbush Sticks to Its Hold Rating for Ikena Oncology (IKNA)
Ikena Oncology GAAP EPS of -$0.28
IKNA Stock Earnings: Ikena Oncology Beats EPS for Q2 2024